{
  "ticker": "GERN",
  "company_name": "Geron Corporation",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07320235",
      "title": "Imetelstat Combinations in Relapsed AML",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed Acute Myeloid Leukemia",
      "start_date": "2026-01",
      "completion_date": "2035-06-15",
      "enrollment": 0,
      "sponsor": "Douglas Tremblay"
    },
    {
      "nct_id": "NCT00594126",
      "title": "Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma",
      "start_date": "2007-11",
      "completion_date": "2011-07",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT01243073",
      "title": "Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Essential Thrombocythemia, Polycythemia Vera",
      "start_date": "2010-12",
      "completion_date": "2015-04",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT00732056",
      "title": "A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Cancer",
      "start_date": "2008-07",
      "completion_date": "2012-03",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT00718601",
      "title": "Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma",
      "start_date": "2008-07",
      "completion_date": "2011-10",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT05371964",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Myelofibrosis",
      "start_date": "2022-05-04",
      "completion_date": "2028-08",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT00510445",
      "title": "Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Lung Cancer",
      "start_date": "2007-07",
      "completion_date": "2011-04",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT00124189",
      "title": "Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Lymphoproliferative Diseases",
      "start_date": "2005-07",
      "completion_date": "2013-03",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT02598661",
      "title": "Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Myelodysplastic Syndromes",
      "start_date": "2016-01-12",
      "completion_date": "2026-10-13",
      "enrollment": 0,
      "sponsor": "Geron Corporation"
    },
    {
      "nct_id": "NCT01265927",
      "title": "A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Neoplasms",
      "start_date": "2011-01",
      "completion_date": "2015-10",
      "enrollment": 0,
      "sponsor": "Indiana University"
    }
  ],
  "summary": {
    "total_trials": 22,
    "by_phase": {
      "PHASE1": 11,
      "PHASE2": 7,
      "PHASE2, PHASE3": 1,
      "PHASE3": 1,
      "": 1,
      "NA": 1
    },
    "by_status": {
      "RECRUITING": 3,
      "COMPLETED": 14,
      "ACTIVE_NOT_RECRUITING": 3,
      "APPROVED_FOR_MARKETING": 1,
      "WITHDRAWN": 1
    },
    "active_trials": 6,
    "completed_trials": 14,
    "conditions": [
      "Acute Respiratory Tract Infections, Diarrhea, Malaria, Neonatal Sepsis, Birth Asphyxia",
      "Breast Cancer",
      "Breast Neoplasms",
      "Chronic Lymphoproliferative Diseases",
      "Essential Thrombocythemia, Polycythemia Vera",
      "Locally Recurrent or Metastatic Breast Cancer",
      "Lung Cancer",
      "Multiple Myeloma",
      "Myelodysplastic Syndromes",
      "Myelodysplastic Syndromes, Acute Myeloid Leukemia",
      "Myelofibrosis",
      "Neuroblastoma",
      "Non-small Cell Lung Cancer",
      "Primary Myelofibrosis, Secondary Myelofibrosis, Myeloid Malignancies",
      "Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia",
      "Relapsed Acute Myeloid Leukemia",
      "Solid Tumor Malignancies"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:32.422152",
    "search_query": "Geron Corporation",
    "url": "https://clinicaltrials.gov/search?term=Geron+Corporation"
  }
}